Loading…
IMA
ImageneBio, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 45175G207
$5.34+0.19%Price as of Aug 29, 18:41 UTC · updated once a day, after the close
Key metrics
- Market cap
- $60.74M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$4.73
- ROE
- -82.68%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- —
- 52-week high
- $13.98
- 52-week low
- $3.94
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -96.3% over 5Y.
today you would have $31.17▼ -96.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 3 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $6.90 | $19.68 | $23.64 | |
| P/S | 62.9x | 96.4x | 62.9x | 33.2x |
| P/B | — | 0.6x | — | — |
| EPS | -$9.64 | -$4.33 | -$2.87 | |
| Profit margin | -1044.80% | -5668.63% | -1044.80% | -265.61% |
| ROE | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HYPDHyperion Defi Inc | $3.92 | — | 0.6x | — | 9.55% | $60.84M |
| TLPHTalphera Inc | $1.20 | — | 3.3x | — | -143.36% | $62.29M |
| XLOXilio Therapeutics, Inc. | $9.00 | — | 1.2x | — | -55.03% | $59.22M |
| SERSerina Therapeutics, Inc. | $2.46 |
About the company
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
- 18
- San Diego, United States
Company description provided by Yahoo Finance.